Factors and Outcomes Associated With Postpartum Cabergoline Use
Study Details
Study Description
Brief Summary
Cabergoline is frequently being requested by many postpartum women with a live newborn to suppress lactation. The aim of the study is to investigate which women desire such an intervention, and what side effects they are experiencing.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
Cabergoline is a dopamine receptor agonist. Outside of the United States, it is occasionally used to suppress lactation, most commonly after a pregnancy loss or stillbirth. However, the investigators noted that the patient population in Israel has been requesting cabergoline for administration after healthy births, for immediate lactation suppression.
Use of cabergoline after delivery comes with many concerns. One primary concern is that this medication can increase the risk of venous thrombotic events, particularly during postpartum when thrombosis risk is already elevated. Secondly, it may have effects that alter mood, which are similarly concerning during a vulnerable period when postpartum depression and other mental health disorders are common.
Finally, of course, is the issue that so many women are requesting lactation suppression immediately after birth, and therefore will not accrue the neonatal and maternal benefits of lactation.
The investigators want to understand the characteristics, demographics and other factors that lead these women to make this choice, as well as assess their risk of medical and psychological adverse effects from cabergoline used in the postpartum period.
During this study, the investigators will not be prescribing cabergoline or in any way affecting its use. The study will be recruiting as subjects women who requested and received cabergoline prescriptions independently, as is common practice throughout the country.
The study will involve three questionnaires with these subjects: one in the hospital, after birth; one a week after birth; and one 6 weeks after birth. The questionnaires will involve medical history, a validated lactation questionnaire, as well as demographic data. All data will be held in a private, password-locked database.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Postpartum women who requested cabergoline A cohort of postpartum women, after a live birth, who request cabergoline for lactation suppression. |
|
| Control group An age-matched cohort of women after a live birth who have not requested cabergoline for lactation suppression. |
Outcome Measures
Primary Outcome Measures
- Demographics of women requesting cabergoline [immediate postpartum]
Demographics parameter of women requesting cabergoline- age, number of children, profession. Data will be collected using questionnaire
- Number of participants experiencing immediate treatment-related adverse events [immediate postpartum]
Adverse effects experienced by women taking cabergoline within few days after treatment will be recorded using questionnaire
- Number of participants experiencing early treatment-related adverse events [1 week postpartum]
Adverse effects experienced by women taking cabergoline within 1 week after treatment will be recorded using questionnaire with focus on thromboembolic events, and depression or mood changes.
- Number of participants experiencing late treatment-related adverse events [six weeks postpartum]
Adverse effects experienced by women taking cabergoline within 6 weeks after treatment, will be recorded using questionnaire, with focus on thromboembolic events, and depression or mood changes.
Secondary Outcome Measures
- Motivations conducting participants to ask for a lactation suppression drug immediatly after giving birth [immediate postpartum]
Questionnaire assessing motivations expressed by women requesting cabergoline for lactation suppression postpartum, using questionnaire
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Postpartum women
-
After a live birth
-
Requesting cabergoline for lactation suppression
Exclusion Criteria:
- those who request cabergoline for lactation suppression after a stillbirth or pregnancy loss
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Laniado Hospital, The Betty Retter Mother & Baby Medical Center | Netanya | Israel |
Sponsors and Collaborators
- Laniado Hospital
Investigators
- Principal Investigator: Sarit Kalfon, MD, Laniado Hospital
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
- AlSaad D, ElSalem S, Abdulrouf PV, Thomas B, Alsaad T, Ahmed A, AlHail M. A retrospective drug use evaluation of cabergoline for lactation inhibition at a tertiary care teaching hospital in Qatar. Ther Clin Risk Manag. 2016 Feb 9;12:155-60. doi: 10.2147/TCRM.S96298. eCollection 2016.
- Ben Natan M, Wiener A, Ben Haim Y. Women׳s intention to exclusively breast feed: The Israeli perspective. Midwifery. 2016 Mar;34:173-177. doi: 10.1016/j.midw.2015.11.013. Epub 2015 Nov 22.
- Eidelman AI. Breastfeeding and the use of human milk: an analysis of the American Academy of Pediatrics 2012 Breastfeeding Policy Statement. Breastfeed Med. 2012 Oct;7(5):323-4. Epub 2012 Sep 4.
- McGuire TM. Drugs affecting milk supply during lactation. Aust Prescr. 2018 Feb;41(1):7-9. doi: 10.18773/austprescr.2018.002. Epub 2018 Feb 1. Review.
- Oladapo OT, Fawole B. Treatments for suppression of lactation. Cochrane Database Syst Rev. 2012 Sep 12;(9):CD005937. doi: 10.1002/14651858.CD005937.pub3. Review.
- Sénat MV, Sentilhes L, Battut A, Benhamou D, Bydlowski S, Chantry A, Deffieux X, Diers F, Doret M, Ducroux-Schouwey C, Fuchs F, Gascoin G, Lebot C, Marcellin L, Plu-Bureau G, Raccah-Tebeka B, Simon E, Bréart G, Marpeau L. Postpartum practice: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol. 2016 Jul;202:1-8. doi: 10.1016/j.ejogrb.2016.04.032. Epub 2016 Apr 29.
- 0017-19-LND